Fresenius Medical Care stock holds near $23 as investors weigh latest earnings
Published on 08/13/2026 at 09:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius Medical Care AG & Co. KGaA (ISIN DE0005785802) stock is quoted around $23.71 on the New York Stock Exchange, with the latest available close on August 12, 2026 showing a modest 0.67 percent decline for the day as investors reassess the dialysis specialist’s outlook within the broader healthcare space in the United States.
Shares hover around mid-$20 range
According to recent market data compiled by MarketBeat, Fresenius Medical Care’s American depositary shares last traded at $23.71, down $0.16 from the previous level, which translates into a 0.67 percent move as of August 12, 2026, 3:57 p.m. Eastern Time.
At that price point, the group’s valuation sits in the lower-$20s range compared with many US-listed healthcare peers, highlighting how the market continues to price in operational challenges alongside stable global demand for chronic kidney disease treatments.
Earnings and guidance frame the story
The latest quarterly figures available for Fresenius Medical Care cover the period ending June 30, 2026, and investors are watching closely how revenue growth and profitability trends evolve against prior-year levels, especially in the company’s core dialysis services business.
For that most recent quarter, the group reported dialysis-related revenue in the billions of home-currency units, reflecting mid-single-digit percentage growth versus the comparable period a year earlier, while net income showed a smaller improvement, underlining that cost pressures and reimbursement dynamics remain central to the investment case.
More background on Fresenius Medical Care
Explore additional context, long-term performance data, and regulatory filings to better understand how Fresenius Medical Care balances growth, margins, and capital allocation in the dialysis market.
Dialysis products underpin the business
Fresenius Medical Care generates the majority of its sales from dialysis services and related products, ranging from hemodialysis machines and filters to consumables that are used multiple times a week by patients with chronic kidney failure.
A representative product category is its hemodialysis equipment line, which combines treatment hardware with disposables designed to deliver consistent filtration performance while meeting strict regulatory standards in both Europe and the United States.
Stock price context for US investors
As of August 12, 2026, 3:57 p.m. Eastern Time, Fresenius Medical Care’s American depositary shares on the New York Stock Exchange were quoted at $23.71, reflecting a single-day move of minus 0.67 percent and anchoring the stock just below the mid-$20 level that has recently acted as a trading reference point.
Fresenius Medical Care stock at a glance
- Company: Fresenius Medical Care AG & Co. KGaA
- ISIN: DE0005785802
- CUSIP: 358029106
- Ticker: FMS
- Exchange: New York Stock Exchange (ADR)
- Price (as of August 12, 2026, 3:57 p.m. ET): $23.71 USD
- Market cap: value in the billions of USD (as of August 12, 2026)
- Sector / Industry: Health Care / Health Care Providers & Services
- Index membership: constituent of major European indexes
- Next earnings date: not yet officially scheduled
